Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label Study In The Latin America Region Comparing The Safety And Efficacy Of Etanercept With Conventional Dmard Therapy In Subjects With Rheumatoid Arthritis.
Brief Summary: The purpose of this 2 phased, open-label study is to compare the safety and efficacy of etanercept with conventional Disease Modifying Antirheumatic Drug (DMARD) therapy in Latin American subjects with moderate to severe rheumatoid arthritis over 128 weeks. Phase 1 is a randomized 24 week treatment period; Phase 2 is an optional open-label 104 week period that allows the investigator to choose continuation with the phase I treatment or the addition, discontinuation or titration of other DMARD therapy already being utilized for the study.


Options:
A: Arm Label: Open-Label Active Treatment Enrolled from Phase 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Open-Label Active Treatment Enrolled from Phase 3; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Open-Label Active Treatment Enrolled from Phase 2 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Open-Label Active Treatment Enrolled from Phase 3
B: Arm Label: Part A: SAR 100 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part A: SAR 150 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part A: SAR 100 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Placebo (for sarilumab), Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part A: SAR 150 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Placebo (for sarilumab), Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part A: SAR 200 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Placebo (for sarilumab), Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part A: Placebo qw; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for sarilumab), Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part B Cohort 1: Non-selected Doses; Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Placebo (for sarilumab), Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2); Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2); Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2); Type: EXPERIMENTAL; Interventions: Drug: Placebo (for sarilumab), Drug: Methotrexate, Drug: Folic Acid | Intervention Type: DRUG; Name: Sarilumab; Assigned to Arm(s): Part A: SAR 100 mg q2w, Part A: SAR 100 mg qw, Part A: SAR 150 mg q2w, Part A: SAR 150 mg qw, Part A: SAR 200 mg q2w, Part B Cohort 1: Non-selected Doses, Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2), Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2) | Intervention Type: DRUG; Name: Placebo (for sarilumab); Assigned to Arm(s): Part A: Placebo qw, Part A: SAR 100 mg q2w, Part A: SAR 150 mg q2w, Part A: SAR 200 mg q2w, Part B Cohort 1: Non-selected Doses, Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2) | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Part A: Placebo qw, Part A: SAR 100 mg q2w, Part A: SAR 100 mg qw, Part A: SAR 150 mg q2w, Part A: SAR 150 mg qw, Part A: SAR 200 mg q2w, Part B Cohort 1: Non-selected Doses, Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2), Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2), Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2) | Intervention Type: DRUG; Name: Folic Acid; Assigned to Arm(s): Part A: Placebo qw, Part A: SAR 100 mg q2w, Part A: SAR 100 mg qw, Part A: SAR 150 mg q2w, Part A: SAR 150 mg qw, Part A: SAR 200 mg q2w, Part B Cohort 1: Non-selected Doses, Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2), Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2), Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2)
C: Arm Label: Phase 1 Etanercept + methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Phase 1: Etanercept, Drug: Phase 1: Methotrexate, Drug: Phase 2: Optional ETN, SSZ, HCQ, MTX | Arm Label: Phase 1 Conventional DMARD (SSZ or HCQ) + MTX; Type: ACTIVE_COMPARATOR; Interventions: Drug: Phase 1: Methotrexate, Drug: Phase 1: Conventiaonal DMARD | Intervention Type: BIOLOGICAL; Name: Phase 1: Etanercept; Assigned to Arm(s): Phase 1 Etanercept + methotrexate | Intervention Type: DRUG; Name: Phase 1: Methotrexate; Assigned to Arm(s): Phase 1 Etanercept + methotrexate | Intervention Type: DRUG; Name: Phase 2: Optional ETN, SSZ, HCQ, MTX; Assigned to Arm(s): Phase 1 Etanercept + methotrexate | Intervention Type: DRUG; Name: Phase 1: Methotrexate; Assigned to Arm(s): Phase 1 Conventional DMARD (SSZ or HCQ) + MTX | Intervention Type: DRUG; Name: Phase 1: Conventiaonal DMARD; Assigned to Arm(s): Phase 1 Conventional DMARD (SSZ or HCQ) + MTX
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo, Drug: MTX | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: Infliximab, Drug: MTX | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: MTX; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Infliximab; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: MTX; Assigned to Arm(s): 2

Answer: C